Clinical Trial Update: A Phase 2 Study to Investigate the Efficacy and Safety of Zelicapavir in Participants Aged ≥28 Days to ≤36 Months of Age Infected With Respiratory Syncytial Virus [Phase 2]

View source ↗

Summary

This is a Phase 2 clinical trial to evaluate the efficacy and safety of Zelicapavir in participants aged 28 days to 36 months with Respiratory Syncytial Virus i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Respiratory Syncytial Virus Infection

Drugs mentioned

• Zelicapavir (EDP-938)

Snippet

Sponsor: Enanta Pharmaceuticals, Inc | Conditions: RSV Infection, RSV | Phase 2 | Status: NOT_YET_RECRUITING